HC Wainwright Issues Pessimistic Forecast for Jasper Therapeutics (NASDAQ:JSPR) Stock Price

Jasper Therapeutics (NASDAQ:JSPR) had its price target reduced by stock analysts at HC Wainwright from $60.00 to $40.00 in a report issued on Friday,Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price target would suggest a potential upside of 467.38% from the company’s current price. HC Wainwright also issued estimates for Jasper Therapeutics’ Q1 2025 earnings at ($1.48) EPS, Q2 2025 earnings at ($1.63) EPS, Q3 2025 earnings at ($1.78) EPS, Q4 2025 earnings at ($1.93) EPS, FY2025 earnings at ($6.83) EPS, FY2026 earnings at ($8.17) EPS, FY2027 earnings at ($9.50) EPS, FY2028 earnings at ($10.61) EPS and FY2029 earnings at ($10.81) EPS.

Other analysts have also recently issued research reports about the company. BMO Capital Markets assumed coverage on Jasper Therapeutics in a research report on Friday, December 6th. They set an “outperform” rating and a $63.00 price objective for the company. JMP Securities reiterated a “market outperform” rating and issued a $70.00 price objective on shares of Jasper Therapeutics in a research note on Monday, January 6th. Finally, Royal Bank of Canada dropped their price objective on shares of Jasper Therapeutics from $68.00 to $48.00 and set an “outperform” rating on the stock in a report on Thursday. Ten analysts have rated the stock with a buy rating, According to MarketBeat, Jasper Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $67.75.

Jasper Therapeutics Trading Up 0.9 %

NASDAQ:JSPR opened at $7.05 on Friday. The company has a market cap of $105.76 million, a PE ratio of -1.49 and a beta of 2.18. The company has a 50 day simple moving average of $21.09 and a two-hundred day simple moving average of $20.16. Jasper Therapeutics has a 12 month low of $6.57 and a 12 month high of $31.01.

Institutional Trading of Jasper Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of JSPR. JPMorgan Chase & Co. increased its stake in Jasper Therapeutics by 239.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 16,391 shares of the company’s stock worth $308,000 after buying an additional 11,567 shares in the last quarter. Barclays PLC grew its position in shares of Jasper Therapeutics by 320.7% during the third quarter. Barclays PLC now owns 16,146 shares of the company’s stock worth $304,000 after purchasing an additional 12,308 shares in the last quarter. Jane Street Group LLC bought a new stake in Jasper Therapeutics during the 3rd quarter valued at approximately $251,000. Wellington Management Group LLP purchased a new position in Jasper Therapeutics in the 3rd quarter worth approximately $447,000. Finally, State Street Corp boosted its stake in Jasper Therapeutics by 12.3% in the 3rd quarter. State Street Corp now owns 214,883 shares of the company’s stock worth $4,042,000 after purchasing an additional 23,564 shares during the period. 79.85% of the stock is currently owned by institutional investors.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.